Table 1 Levels of striatal dopamine and 5-HT and their metabolites 9 days after treatment with MPTP.

From: Tiagabine Protects Dopaminergic Neurons against Neurotoxins by Inhibiting Microglial Activation

 

Saline (n = 4)

MPTP (n = 7)

Tiagabine + MPTP (n = 5)

DA

100 ± 12.99

17.08 ± 1.74***

24.85 ± 1.96***

DOPAC

100 ± 18.36

42.2 ± 5.97**

35.31 ± 8.34**

DOPAC/DA

100 ± 22.52

240.2 ± 19.37**

131.98 ± 28.91^^

HVA

100 ± 9.55

76.78 ± 5.54*

47.21 ± 8.64**^

HVA/DA

100 ± 14.76

468.85 ± 60.8***

177.99 ± 24.41*^^

5-HT

100 ± 11.60

79.92 ± 10.47

45.64 ± 3.81***

5-HIAA

100 ± 8.14

106.54 ± 9.17

58.68 ± 3.60**^^

5-HIAA/5-HT

100 ± 13.89

136.36 ± 8.38*

127.59 ± 12.55

  1. Data are presented as a percentage of the control. *p < 0.05, **p < 0.01 and ***p < 0.001, versus the saline control group; ^p < 0.05 and ^^p < 0.01, versus the MPTP-treated group.
Back to article page